Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Respiratory Syncytial Virus Disease

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Setting the Stage for 2018: How the Changes in the American Joint Committee on Cancer/Union for International Cancer Control <i>Cancer Staging Manual</i> Eighth Edition Impact Radiologists.

AJNR. American journal of neuroradiology·2017

Same author

Neonatal Acute Kidney Injury: A Survey of Neonatologists' and Nephrologists' Perceptions and Practice Management.

American journal of perinatology·2017

Same author

Advanced dual-energy CT applications for the evaluation of the soft tissues of the neck.

Clinical radiology·2017

Same author

Feasibility analysis of the parametric response map as an early predictor of treatment efficacy in head and neck cancer.

AJNR. American journal of neuroradiology·2015

Same author

Citrate modulates lipopolysaccharide-induced monocyte inflammatory responses.

Clinical and experimental immunology·2015

Same author

Pain in primary Sjögren's syndrome: the role of catastrophizing and negative illness perceptions.

Scandinavian journal of rheumatology·2014

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Natalizumab (Tysabri).

D T Selewski¹, G V Shah, B M Segal

¹Department of Pediatrics, Division of Pediatric Nephrology, University of Michigan, C.S. Mott Children's Hospital, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-7789, USA. dselewsk@med.umich.edu

AJNR. American Journal of Neuroradiology

|August 7, 2010

Summary

This summary is machine-generated.

Natalizumab, a monoclonal antibody, effectively treats relapsing-remitting multiple sclerosis by inhibiting leukocyte adhesion. This review covers its mechanism and clinical use in MS management.

More Related Videos

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

Related Experiment Videos

Last Updated: Jun 10, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

Area of Science:

Immunology
Neurology
Pharmacology

Background:

Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
Current treatments aim to reduce disease activity and manage symptoms.
Natalizumab represents a significant advancement in MS therapy.

Purpose of the Study:

To review the mechanism of action of Natalizumab.
To discuss the clinical role of Natalizumab in treating relapsing-remitting MS.
To provide an overview of Natalizumab as a therapeutic agent.

Main Methods:

Review of existing literature on Natalizumab.
Analysis of clinical trial data for Natalizumab in MS.
Examination of Natalizumab's pharmacological properties.

Main Results:

Natalizumab selectively inhibits leukocyte adhesion to endothelial cells.
It is the first FDA-approved monoclonal antibody for relapsing-remitting MS.
Demonstrated efficacy in reducing MS relapses and new brain lesions.

Conclusions:

Natalizumab offers a targeted approach to MS treatment.
Its mechanism of action is crucial for its therapeutic effect.
Natalizumab plays a vital role in the management of relapsing-remitting MS.